VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

WCLC 2022 | Recurrent irAEs observed with sequential sotorasib after chemoimmunotherapy for KRASG12C NSCLC

Wanda Cui, MBBS, BMedSci, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses a case study of a patient with KRASG12C non-small cell lung cancer (NSCLC) who had substantial immune-related adverse events during their sotorasib treatment after first-line chemoimmunotherapy. Sotorasib is currently approved for second-line KRASG12C-mutant NSCLC and given chemoimmunotherapy or immunotherapy alone is first-line treatment for NSCLC, there will be a significant number of real-world patients having this sequential treatment regimen. Synergistic toxicity and an increase in adverse events has been observed with sotorasib and other tyrosine kinase inhibitors (TKIs), such as osimertanib, in patients with NSCLC, particularly in patients who have transitioned from immunotherapy to TKIs within 3-months or less. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter